Pfizer has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration, which includes most-favoured-nation pricing and participation in a new website, TrumpRx, for direct drug purchases. The deal aims to help patients and state budgets, although the extent of price changes remains unclear. Trump also announced a $70 billion investment in US manufacturing by Pfizer. Critics note that while some may benefit, the overall impact on drug pricing may be limited. Teljes cikk (Euronews.com)